Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1953 2
1957 1
1959 5
1960 2
1962 3
1964 2
1965 2
1966 3
1967 5
1968 6
1969 8
1970 10
1971 5
1972 9
1973 11
1974 5
1975 8
1976 10
1977 13
1978 10
1979 10
1980 11
1981 6
1982 14
1983 10
1984 12
1985 12
1986 17
1987 21
1988 24
1989 24
1990 26
1991 24
1992 31
1993 42
1994 54
1995 48
1996 71
1997 78
1998 77
1999 104
2000 125
2001 124
2002 119
2003 188
2004 250
2005 266
2006 274
2007 347
2008 328
2009 376
2010 413
2011 508
2012 547
2013 554
2014 530
2015 579
2016 553
2017 559
2018 506
2019 523
2020 587
2021 599
2022 442
Text availability
Article attribute
Article type
Publication date

Search Results

9,095 results
Results by year
Filters applied: . Clear all
Page 1
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin HM, Liu Y, Vranceanu F, Niu H, Zhang P, Popat S. Camidge DR, et al. Among authors: lee kh. J Thorac Oncol. 2021 Dec;16(12):2091-2108. doi: 10.1016/j.jtho.2021.07.035. Epub 2021 Sep 16. J Thorac Oncol. 2021. PMID: 34537440 Free article. Clinical Trial.
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, Özgüroğlu M, Lee KH, Kato T, de Wit M, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ. Spigel DR, et al. Among authors: lee kh. J Clin Oncol. 2022 Apr 20;40(12):1301-1311. doi: 10.1200/JCO.21.01308. Epub 2022 Feb 2. J Clin Oncol. 2022. PMID: 35108059 Free PMC article. Clinical Trial.
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.
Oh DY, Lee KH, Lee DW, Yoon J, Kim TY, Bang JH, Nam AR, Oh KS, Kim JM, Lee Y, Guthrie V, McCoon P, Li W, Wu S, Zhang Q, Rebelatto MC, Kim JW. Oh DY, et al. Among authors: lee kh. Lancet Gastroenterol Hepatol. 2022 Jun;7(6):522-532. doi: 10.1016/S2468-1253(22)00043-7. Epub 2022 Mar 9. Lancet Gastroenterol Hepatol. 2022. PMID: 35278356 Clinical Trial.
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.
Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, Lee KH, Massuti B, Hiret S, Yang JCH, Barlesi F, Lee DH, Ares LP, Hsieh RW, Patil NS, Twomey P, Yang X, Meng R, Johnson ML. Cho BC, et al. Among authors: lee kh. Lancet Oncol. 2022 Jun;23(6):781-792. doi: 10.1016/S1470-2045(22)00226-1. Epub 2022 May 13. Lancet Oncol. 2022. PMID: 35576957 Clinical Trial.
Induction and Maintenance Treatment of Lupus Nephritis: A Comprehensive Review of Meta-Analyses.
Shin JI, Li H, Park S, Yang JW, Lee KH, Jo Y, Park S, Oh J, Kim H, An HJ, Jeong G, Jung H, Lee HJ, Kim JS, Nam SW, Koyanagi A, Jacob L, Hwang J, Yon DK, Lee SW, Tizaoui K, Kronbichler A, Kim JH, Smith L. Shin JI, et al. Among authors: lee kh. J Clin Med. 2022 Jan 11;11(2):343. doi: 10.3390/jcm11020343. J Clin Med. 2022. PMID: 35054037 Free PMC article. Review.
Kim H, Lee KH. Kim H, et al. Among authors: lee kh. Chest. 2022 May;161(5):e329-e330. doi: 10.1016/j.chest.2022.01.010. Chest. 2022. PMID: 35526911 No abstract available.
A large-scale meta-analytic atlas of mental health problems prevalence during the COVID-19 early pandemic.
Dragioti E, Li H, Tsitsas G, Lee KH, Choi J, Kim J, Choi YJ, Tsamakis K, Estradé A, Agorastos A, Vancampfort D, Tsiptsios D, Thompson T, Mosina A, Vakadaris G, Fusar-Poli P, Carvalho AF, Correll CU, Han YJ, Park S, Il Shin J, Solmi M. Dragioti E, et al. Among authors: lee kh. J Med Virol. 2022 May;94(5):1935-1949. doi: 10.1002/jmv.27549. Epub 2022 Jan 9. J Med Virol. 2022. PMID: 34958144 Free PMC article.
Adrenal hemangioblastoma.
Koo JY, Lee KH, Choi JH, Chung HS, Choi C. Koo JY, et al. Among authors: lee kh. J Pathol Transl Med. 2022 May;56(3):161-166. doi: 10.4132/jptm.2021.12.28. Epub 2022 Feb 28. J Pathol Transl Med. 2022. PMID: 35209700 Free PMC article.
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.
O'Byrne KJ, Lee KH, Kim SW, Park K, Nishio M, Sakai H, Ohe Y, Fukuhara T, Kang JH, Daga H, Yu CJ, Hotta K, Tanaka H, Takeda M, Yokoyama T, Nathan FE, Lee JS. O'Byrne KJ, et al. Among authors: lee kh. ESMO Open. 2022 Feb;7(1):100394. doi: 10.1016/j.esmoop.2022.100394. Epub 2022 Feb 12. ESMO Open. 2022. PMID: 35158207 Free PMC article. Clinical Trial.
Pediatric Single-Sided Deafness.
Hunter JB, Yancey KL, Lee KH. Hunter JB, et al. Among authors: lee kh. Otolaryngol Clin North Am. 2022 Dec;55(6):1139-1149. doi: 10.1016/j.otc.2022.07.003. Otolaryngol Clin North Am. 2022. PMID: 36371131 Review.
9,095 results